Antidepressants Global Market Report 2023 – By Product (Selective Serotonin Reuptake Inhibitor (SSRI), Serotoninnorepinephrine Reuptake Inhibitor (SNRI), Tricyclic Antidepressant (TCA), Monoamine Oxidase Inhibitor (MAOI)), By Drug Class (Monoamine Oxidase Inhibitors, Serotonin Antagonist And Reuptake Inhibitors, SerotoninNorepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants), By Depressive Disorder (Major Depressive Disorder, ObsessiveCompulsive Disorder, Generalized Anxiety Disorder, Panic Disorder) – Market Size, Trends, And Global Forecast 2023-2032

Inflammatory bowel disease treatment refers to anti-inflammatory medications that are commonly used to treat mild to moderate ulcerative colitis. Aminosalicylates such as mesalamine (Delzicol, Rowasa, and other brands), balsalazide (Colazal), and olsalazine are anti-inflammatories (Dipentum). The main drug class of inflammatory bowel disease treatment include aminosalicylates, corticosteroids, TNF inhibitors, IL inhibitors, anti-integrin, JAK inhibitors, and others. Aminosalicylates refer to a class of medications used to treat and prevent ulcerative colitis flare-ups and Crohn's disease. The functioning of aminosalicylates is based on inhibiting the production of cyclo-oxygenase and prostaglandin, thromboxane synthetase, platelet-activating factor synthetase, and interleukin-1 by macrophages. Both orally and injectable administered inflammatory bowel disease treatment are used in the treatment of Crohn’s disease and ulcerative colitis. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The global inflammatory bowel disease treatment market is segmented - 1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes 2) By Type: Crohn's Disease, Ulcerative Colitis 3) By Route of Administration: Oral, Injectable 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy The global inflammatory bowel disease treatment market size will grow from $20.39 billion in 2022 to $21.3 billion in 2023 at a compound annual growth rate (CAGR) of 4.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the inflammatory bowel disease treatment is expected to grow to $25.74 billion in 2027 at a CAGR of 4.8%. The rising prevalence of Crohn’s disease and ulcerative colitis is significantly driving the inflammatory bowel disease treatment market. Crohn’s disease and ulcerative colitis are types of inflammatory bowel diseases (IBD) that cause inflammation and ulcers (sores) in the digestive tracts. The rising cases of Crohn’s disease and ulcerative colitis are expected to boost demand for inflammatory bowel disease treatments, as they are widely used to reduce bowel inflammation and reduce and prevent medical complications. For instance, according to March 2022 research published in the United States National Library of Medicine, a US-based medical library, around 1.6 million Americans currently suffer from inflammatory bowel disease (Crohn’s disease or ulcerative colitis) and around 70,000 new cases of IBD are diagnosed every year in the USA. Hence, the rising prevalence of Crohn's disease and ulcerative colitis is expected to drive the inflammatory bowel disease treatment market growth. Major players in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen, Johnson & Johnson, Amgen Inc., UCB SA, Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co, Pfizer Inc., Abbott Laboratories, Janssen Biotech Inc., Eli Lilly, Allergan plc, Alkem Laboratories Limited, and Bausch Health Companies Inc. Technological advancement is a key trend gaining popularity in the inflammatory bowel disease treatment market. The key players in the inflammatory bowel disease treatment market are focusing on using technology such as artificial intelligence (AI) for the drug discovery process as well as offering advanced but new inflammatory bowel disease treatments. To attain their technological innovations, key players and technology companies are partnering to leverage each other's competencies and technology to develop new treatments and strengthen their key position in the market. For instance, in May 2021, CytoReason, an Israeli technology start-up developing a computational model of the human body, partnered with Ferring Pharmaceuticals, a Switzerland-based multinational pharmaceutical company to develop new inflammatory bowel disease treatments (IBD) using artificial intelligence technology during the drug discovery process. Ferring's medical expertise will be combined with CytoReason's artificial intelligence (AI) technology to create cell-centred illness models. The AI technology enables scientists to gain critical information on the body’s functioning and treats diseases at the cellular level. In March 2022, Pfizer, Inc., a US-based pharmaceutical and biotechnology company, acquired Arena Pharmaceuticals, Inc., for an amount of $6.7 billion. Through this acquisition, Pfizer will increase its Inflammation and Immunology therapeutic area research capabilities, develop therapies for treatment of immuno-inflammatory diseases, and continue the clinical development of current drug candidates. Arena Pharmaceuticals, Inc., is a US-based biopharmaceutical company specializing in the development of novel prospective treatments for the treatment of various immuno-inflammatory illnesses. North America was the largest region in the inflammatory bowel disease treatment market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the inflammatory bowel disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The inflammatory bowel disease treatment market includes revenues earned by entities by reducing the inflammation that triggers the signs and symptoms. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced.It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The inflammatory bowel disease treatment market research report is one of a series of new reports from The Business Research Company that provides inflammatory bowel disease treatment market statistics, including inflammatory bowel disease treatment industry global market size, regional shares, competitors with an inflammatory bowel disease treatment market share, detailed inflammatory bowel disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the inflammatory bowel disease treatment industry. This inflammatory bowel disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Dermatitis refer to the inhibitors that treat skin inflammation, which is characterised by itchy rashes on swollen and reddish skin, in the outer layer of the body. It is a general term that describes a common skin irritation. The main classes of drugs in dermatitis are corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators, and interleukin inhibitors. Corticosteroids are a group of steroid hormones generated by vertebrates' adrenal cortex and are also synthetic equivalents of these hormones. The different routes of administration include topical, oral, and injectable and are used in cancer, blood disorders, chronic diseases, and infectious diseases. It is distributed through various channels such as hospitals, retail pharmacies, drug stores, and online or mail pharmacies. The global dermatitis market is segmented - 1) By Drug Class: Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors 2) By Distribution Channel: Hospital, Retail Pharmacies, Drug Stores, Online Or Mail Pharmacies 3) By Route Of Application: Topical, Oral, Injectable 4) By Application: Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases The global dermatitis market size will grow from $6.46 billion in 2022 to $6.89 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global dermatitis is expected to grow to $8.57 billion in 2027 at a CAGR of 5.6%. Growth in the atopic dermatitis market is primarily driven by the increasing global prevalence of the disease. The prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in adults. The rising cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for medicines to cure this disease. For example, according to the allergy asthma network 2020, approximately 31.6 million people in the United States have some form of atopic dermatitis. The prevalence of atopic dermatitis globally in children have 15-20 percent and in adults have 1 to 3 percent. Major players in the dermatitis market are LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer HealthCare, Encore Dermatology Inc., Meda Pharmaceuticals, Allergan PLC. (Republic of Ireland) and Bristol-Myers Squibb. The strict government regulations are one of the restraints for the dermatitis market. Atopic Dermatitis (eczema) usually occurs at a very early stage (0-5 years). To find the efficacy and efficiency of the drug, it has to be tried on every type of patient. The effects of certain drugs in adults are quite different than in children, as a reasonable result of the clinical trial cannot be used for the production of drugs that will be served to the children. This hinders the research and requires more effort in clearing regulations set by FDA. For example, as the patient population is largely children, the FDA in its CFR Code Title 21, Part 50 Protection of Human Subjects, and subpart D has laid down guidelines for the additional safeguard for children in clinical investigation. The regulation complies with the Children’s Health Act of 2000 which requires all children subjected to clinical trials to be given additional protection. The dermatitis market has witnessed a trend of increasing mergers and acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today's world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolios and improve their market presence. Companies are also strategically making M&As to reduce competition and increase the scalability of their businesses. For instance, in January 2020, Eli Lilly and Company, a US-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of human drugs, acquired Dermira, Inc. for an amount of $1.1 billion. Through this acquisition, Lebrikizumab, an innovative, experimental monoclonal antibody, has been added to the immunology pipeline and marketed dermatology medicines in the product portfolio of Eli Lilly for the treatment of moderate-to-severe atopic dermatitis in patients 12 years of age and older. Dermira, Inc. is a US-based biopharmaceutical company pioneering in the discovery and development of novel therapies for dermatology patients. The dermatitis market is governed by several regulatory bodies that require the drug manufacturers to get approvals from the concerned authorities before launching their medicines into the market. Two such major regulatory bodies are PMDA (Japan) and CDSCO (India) which carry out quality checks before declaring the drugs suitable for consumption. PMDA reviews the products to ensure the safety, quality, and efficacy of pharmaceuticals and then approves the products that are suitable in every parameter. Similarly, CDSCO is the central drug authority that is responsible for the approval of new drugs in India. These tedious approval processes make the drugs more effective and safe thereby having a positive impact on the dermatitis drugs market. North America was the largest region in the dermatitis market in 2022. Middle East is expected to be the fastest-growing region in the dermatitis market report during the forecast period. The regions covered in the dermatitis industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The dermatitis market consists of sales of Stasis dermatitis, atopic dermatitis, and irritant contact dermatitis. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The dermatitis market research report is one of a series of new reports from The Business Research Company that provides dermatitis market statistics, including dermatitis industry global market size, regional shares, competitors with a dermatitis market share, detailed dermatitis market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatitis industry. This dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Bipolar disorder therapeutics refer to medication, including mood stabilizers, antidepressants, antipsychotics, and psychological counseling, to control symptoms. The bipolar disorder therapeutic is used in the treatment and management of bipolar disorders. The main types of drugs in bipolar disorder therapeutics are mood stabilizers, antipsychotic drugs, antidepressant drugs, and other drugs. Mood stabilizers refer to a class of medications used in the management and treatment of bipolar disorders. The different mechanisms include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, beta-blockers, and others. These are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The global bipolar disorder therapeutics market is segmented - 1) By Drug Class: Mood Stabilizers, Antipsychotic Drugs, Antidepressant Drugs, Other Drugs 2) By Mechanism: Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Benzodiazepines, Beta-Blockers, Other Mechanisms 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The global bipolar disorder therapeutics market size grew from $6.51 billion in 2022 to $6.93 billion in 2023 at a compound annual growth rate (CAGR) of 6.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global bipolar disorder therapeutics is expected to grow to $8.36 billion in 2027 at a CAGR of 4.8%. The increase in the prevalence of bipolar disorder is expected to propel the growth of the bipolar disorder therapeutics market going forward. Bipolar disorder refers to a disabling illness that is associated with depressive mood swings and includes symptoms such as irregular sleep, low motivation, and loss of interest in daily activities. Population growth and aging are leading to an increase in the burden of bipolar disorder over time. As a result, an increase in the prevalence of bipolar disorder increases the demand for the bipolar disorder therapeutics market. For instance, according to the Depression and Bipolar Support Alliance, a US-based non-profit association providing support to the patients of depression or bipolar disorder, in 2021, approximately 5.7 million adult Americans which was about 2.6% of the U.S. population were affected by bipolar disorder. The median age of the onset of bipolar disorder is 25 years, and more than two-thirds of people suffering from bipolar disorder had at least one relative with the illness. Therefore, the increase in the prevalence of bipolar disorder is driving the growth of the bipolar disorder therapeutics market. Major players in the bipolar disorder therapeutics market are AbbVie Inc., Pfizer Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline PLC, Januaryssen Pharmaceuticals, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Validus Pharmaceuticals, Eli Lilly and Company, Gedeon Richter PLC., Sumitomo Pharma Co. Ltd., and H. Lundbeck A/S. Strategic partnerships have emerged as a key trend gaining popularity in the bipolar disorder therapeutics market. Major companies operating in the bipolar disorder therapeutics sector are focused on partnerships to reinforce their position. For instance, in October 2021, Mindpax Inc., a Germany-based digital technology company operating in the bipolar disorder therapeutics market, partnered with Eversana Life Science Services LLC, a US-based life sciences company operating in the bipolar disorder therapeutics market. Through this partnership, both companies will develop remote clinical assessments and targeted digital therapy to improve patients' clinical conditions and provide personalized therapeutic interventions to bipolar patients. Furthermore, in November 2020, Biogen, a US-based biotechnology company, partnered with Sage Therapeutics, a US-based company that develops novel therapies including bipolar. Through this partnership, both businesses will work together to commercialize zuranolone (SAGE-217) for significant postpartum depression (PPD), depressive disorder (MDD), and other psychiatric diseases. In May 2020, AbbVie, a US-based biopharmaceutical company, acquired Allergan plc for a deal amount of $63 billion. AbbVie's revenue base is expected to broaden and diversify, complementing existing leadership positions in immunology (with Humira (adalimumab) and hematologic oncology (with Imbruvica (ibrutinib) and Venclexta (upadacitinib), and the recently launched Skyrizi (risankizumab) and Rinvoq (upadacitinib) (venetoclax). Allergan is an Ireland-based specialty pharmaceutical company that develops pharmaceuticals and biosimilar products, including those for bipolar disorder. North America was the largest region in the bipolar disorder therapeutics market in 2022. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the bipolar disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the bipolar disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The bipolar disorder therapeutics market includes revenues earned by entities by family-focused therapy, interpersonal and social rhythm therapy, cognitive behavioral therapy and dialectical behavior therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The bipolar disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides bipolar disorder therapeutics market statistics, including bipolar disorder therapeutics industry global market size, regional shares, competitors with a bipolar disorder therapeutics market share, detailed bipolar disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the bipolar disorder therapeutics industry. This bipolar disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nootropics refer to memory-enhancing substances that have a stimulation effect. The nootropics help boost brain performance. The nootropics include caffeine, creatine, vitamins, and minerals, which are used to increase memory, strength, or other cognitive functions. They may affect memory, thinking, or other mental functions, but they do not treat the diseases. The main types of drugs in nootropics are prescription nootropics and OTC nootropics. The prescription nootropics help to provide stimulant effects, counteracting the symptoms of medical conditions such as attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, or narcolepsy. The various forms include capsules or tablets, powder, drinks, and others, and are distributed through several channels, such as online and offline. The nootropics are used in memory enhancement, mood and depression treatment, attention and focus, longevity and anti-aging, sleep and recovery, and anxiety treatment. The global nootropics market is segmented - 1) By Drug Type: Prescription Nootropics, OTC Nootropics 2) By Form: Capsules or Tablets, Powder, Drinks, Other Forms 3) By Distribution Channel: Offline, Online 4) By Application: Memory Enhancement, Mood and Depression, Attention and Focus, Longevity and Anti-aging, Sleep and Recovery, Anxiety The global nootropics market size grew from $3.97 billion in 2022 to $4.64 billion in 2023 at a compound annual growth rate (CAGR) of 17.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the nootropics market is expected to grow to $7.87 billion in 2027 at a CAGR of 14.1%. The increasing expenditure on health and wellness is expected to propel the growth of the nootropics market going forward. Health and wellness are generally defined as a method that an individual respects to reach mental health and physical wellbeing. Mental and physical health involves diving deep into the health and wellness industry. Nootropics are useful in maintaining an individual's health and wellness, as a result, if the demand for healthcare and wellness is increasing, so will the need for nootropics. For instance, according to Global Wellness Institute, a US-based non-profit organization, the global mental wellness market was valued at $122 billion in 2019 and grew by 7.2%, reaching $131 billion in 2020. Therefore, the increasing expenditure on healthcare and wellness drives the nootropics market. Major players in the nootropics market are Accelerated Intelligence Inc., AlternaScript, HVMN, Mental Mojo LLC., Peak Nootropics, PureLife Bioscience Co. Ltd., Blue Brain Boost, NooCube, Mind Lab Pro, TruBrain, Neu Drinks, Superior Supplement Manufacturing, Equinox Nutraceuticals, and Natural Stacks. The adoption of vegan nootropics is gaining popularity in the global nootropics market. Major companies operating in the nootropics market are going to new organic product innovations to meet consumer demand and sustain their position in the market. For instance, in July 2022, BioAdaptives Inc., a US-based manufacturer of natural plant and algae-based supplements, launched MindMemory, which is an advanced nootropic intended to enhance memory, mental focus, and concentration. The new product has a gradual and smooth effect and unlike coffee, it does not produce sudden rush of adrenaline. In April 2021, Unilever Global, a UK-based company that manufactures nootropics, acquired Onnit for an undisclosed amount. Through this acquisition, Onnit entirely sets Unilever in an increasing portfolio of advanced wellness and supplement brands that include olly, equilibria, liquid I.V., and SmartyPants Vitamins. Onnit is a US-based company operating in nootropics and a specialist in functional nutrition, fitness, mental, and emotional wellness needs. North America was the largest region in the nootropics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nootropics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the nootropics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The nootropics market includes revenues earned by entities by modafinil (provigil), adderall, methylphenidate (ritalin), memantine (axura), caffeine, l-theanine, and omega-3 fatty acids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The nootropics market research report is one of a series of new reports from The Business Research Company that provides nootropics market statistics, including nootropics industry global market size, regional shares, competitors with a nootropics market share, detailed nootropics market segments, market trends and opportunities, and any further data you may need to thrive in the nootropics industry. This nootropics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Psychiatrists provide the diagnosis, treatment, and prevention of mental, emotional, and behavioral disorders. Psychiatrists are licensed practitioners with a degree of M.D. (Doctor of Medicine) or D.O. (Doctor of Osteopathic Medicine) who provide palliative care and treat psychosomatic disorders, mental disorders, and others. They operate private or group practices in their own offices (e.g., centers, clinics) or in the facilities of others, such as hospitals or health maintenance organizations (HMO) medical centers. The main mental disorder types of psychiatrists are alcohol abuse mental and behavioral disorders, psychoactive substances that use mental and behavioral disorders, schizophrenia, schizotypal and delusional disorders, mood (anxiety and depression) disorders, and other mental and behavioral disorders. The patient types are inpatient and outpatient. The psychology types are social, abnormal, biological, and others. The global psychiatrists market is segmented – 1) By Mental Disorder Type: Alcohol Abuse Mental And Behavioral Disorders, Psychoactive Substance Use Mental And Behavioral Disorders,Schizophrenia, Schizotypal And Delusional Disorders, Mood (Anxiety And Depression) Disorders, and Other Mental And Behavioral Disorders 2) By Patient Type: Inpatient, and Outpatient 3) By Psycology Type: Social, Abnormal, Biological, Other Psycology Types The global psychiatrists market size will grow from $147.28 billion in 2022 to $164.01 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of psychiatrists is expected to grow from $231.47 billion in 2027 at a CAGR of 9.0%. The rising government support for mental health reforms is expected to propel the growth of the psychiatrist market going forward. Support for mental health resources led to a demand for mental care and drove the psychiatrists market. For instance, according to Business Insider, a US-based financial and business news website, Chile announced an over 300% increase in the mental health budget in 2021 and Canada announced a $1 billion fund allocation for mental health in its Budget 2021. Therefore, rising government support for mental health reforms is driving the growth of the psychiatrists market. The major players covered in the psychiatrists market are UK NHS, Universal Health Services, Massachusetts General Hospital, New York-Presbyterian University Hospital, Mayo Clinic, Johns Hopkins Hospital, McLean Hospital, Mental Health and Neurosciences, Vidyasagar Institute of Mental Health and Neurosciences, Central Institute of Psychiatry, Institute of Behaviour and Allied Sciences. The new studies associated with psychiatric genetics are discovering complex disorders related to mental health are a key trend gaining popularity in the psychiatrists market. Psychiatric genetics studies the role of genetics in the causes of mental health and provides knowledge to improve treatment methods. For instance, scientists discovered causes related to anorexia, an eating disorder. The researchers found that the problems related to this disorder were driven by metabolism. The researchers compared nearly 17,000 anorexia symptomatic people’s DNA with more than 55,000 healthy controls. The study revealed eight genes that linked anorexia to anxiety, depression, and obsessive-compulsive disorder, all of which were expected. Ultimately, these genetic discoveries will provide clues to the major mental disorders. North America was the largest region in the Psychiatrists market in 2022. The regions covered in the psychiatrists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the psychiatrist's market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The psychiatrists market includes revenues earned by entities by providing psychiatrist services such as mental disorder treatments, anxiety disorders treatments, depression treatments, disruptive behavior and dissocial disorders treatments, and neurodevelopmental disorders treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The psychiatrists market research report is one of a series of new reports from The Business Research Company that provides psychiatrists market statistics, including psychiatrists industry global market size, regional shares, competitors with a psychiatrists market share, detailed psychiatrists market segments, market trends and opportunities, and any further data you may need to thrive in the psychiatrists industry. This psychiatrists market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drugs for immunotherapy refer to a kind of medication that offers treatment to either stimulate or suppress the immune system in order to aid the body's protection against cancer, infection, and other disorders. Your immune system is assisted in fighting cancer via immunotherapy, a sort of cancer treatment. The body's immune system aids in the fight against infections and other disorders. The main types of drugs for immunotherapy are monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different areas of therapy include cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and they are used by various sectors such as hospitals and clinics, ambulatory surgical centers, and others. The global drugs for immunotherapy market is segmented - 1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types 2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users The global drugs for immunotherapy market size grew from $208.56 billion in 2022 to $231.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global drugs for immunotherapy is expected to grow from $349.53 billion in 2027 at a CAGR of 10.9%. The drugs for immunotherapy market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. For instance, in February 2022, according to a report shared by the WHO, a Switzerland-based specialized agency of the United Nations responsible for international public health, roughly 10 million deaths, or nearly one in six deaths, will be caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving the drugs for immunotherapy market growth. Major players in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Amgen, Inc., AbbVie, Inc., and Merck & Co. Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca PLC., Johnson & Johnson, and UbiVac. The high cost of drugs for the immunotherapy market is acting as a restraint on the drugs for the immunotherapy market as a smaller number of patients can afford the treatment. Immunotherapy drugs are expensive as they are made specifically for each patient, and investment costs in research and development are high. For instance, Novartis’ Kymriah and Gilead Sciences’ Yescarta are two immunotherapy treatments that cost between $373,000 and $475,000 per patient, depending on the type of cancer. The Yervoy (ipilimumab) drug from Bristol-Myers Squibb, for the treatment of melanoma, a type of skin cancer, costs $120,000 per course of treatment. The high cost of immunotherapy drugs makes them unaffordable, thereby affecting the drugs for immunotherapy market growth. Manufacturers of drugs for immunotherapy market are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilise Illumina’s next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer’s portfolio of assets related to allogeneic CAR-T therapy. Manufacturers of drugs for immunotherapy market are governed by various regulatory bodies, such as the Food and Drug Administration in the USA. The Food and Drug Administration (FDA) regulates drugs and biologics under the authority granted to it by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its amendments. Under this authority, FDA regulates the pre-market testing and marketing approval for all immunotherapeutic agents, either as drugs or biologics, depending on the source and function of the investigational agent. Immunotherapeutic products that are regulated as biologics include antibodies and proteins, and some nucleic acids. In August 2020, Bristol Myers Squibb, a US-based pharmaceutical company that manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders, acquired Dragonfly Therapeutics’ investigational immunotherapy program for $475 million. Through this acquisition, Bristol Myers Squibb will be granted Dragonfly’s extended half-life cytokine DF6002, a monovalent IL-12 immunoglobulin Fc. Dragonfly Therapeutics, Inc. is a US-based discovery-stage company developing drugs to stimulate immune responses against cancer. North America was the largest region in the immunotherapy market in 2022. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, USA. The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metabolic disorders drugs market consists of sales of metabolic disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce metabolic disorders drugs to treat metabolic diseases. This industry includes establishments that produce drugs such as insulin, pramlintide and other drugs to treat diabetes, anti-thyroid drugs to treat hyperthyroidism, and other drugs to treat pituitary gland, adrenal gland and parathyroid gland disorders. The main types of metabolic disorders drugs are anti diabetics drugs, anti-thyroid drugs and others (hyperparathyroidism, hypopituitarism, hypoadrenalism). Antithyroid drugs are medications that either reduce thyroid hormone synthesis (thionamides) or increase thyroid hormone release (iodides). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global metabolic disorders drugs market size is expected to grow from $82.05 billion in 2021 to $90.83 billion in 2022 at a compound annual growth rate (CAGR) of 10.7%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The metabolic disorders drugs market is expected to reach $205.11 billion in 2026 at a CAGR of 22.6%. The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as diabetes and obesity. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of metabolic disorders. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. These factors are expected to increase the patient pool globally, thereby driving the metabolic disorders drugs market during the forecast period. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin. Such factors will negatively impact the attractiveness of the metabolic disorders drugs industry during the forecast period. Companies are focusing on employing artificial intelligence applications to revolutionize the treatment of metabolic disorders. Artificial Intelligence is a machine-based learning which makes use of human intelligence functionalities like reasoning and problem-solving abilities to obtain insights and provide useful information. This technology radically changes the treatment of metabolic syndrome by analyzing large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. 3BIGS, a Korean biodata analysis-based company that studies the relation between diseases, targets and drugs is using AI technology to help researches repurpose the drugs for additional diseases. Major companies in the metabolic disorders drugs market include Novo Nordisk, Eli Lilly And Company, Novartis AG, Sanofi S.A, Merck & Co, GlaxosmithKline, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH and Dainippon Sumitomo Pharma. North America was the largest region in the metabolic disorders drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the metabolic disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the metabolic disorders drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global metabolic disorders drugs market is segmented - 1) By Type: Anti Diabetics Drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The musculoskeletal disorders drugs market consists of sales of musculoskeletal disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce musculoskeletal disorders drugs to treat musculoskeletal disorders such as arthritis, osteoporosis, osteomalacia, and other disorders. This industry includes establishments that produce drugs to treat rheumatoid arthritis, muscle relaxants to reduce muscle pain, and other drugs used in treating osteoarthritis, analgesics drugs, immunosuppressive. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer. The main types of musculoskeletal disorders drugs are drugs for rheumatoid arthritis, muscle relaxants and other musculoskeletal disorders drugs. A muscle relaxant is a medication that causes muscle contractions to cease. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global musculoskeletal disorders drugs market size is expected to grow from $897.45 billion in 2021 to $104.03 billion in 2022 at a compound annual growth rate (CAGR) of 6.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The musculoskeletal disorders drugs market is expected to reach $163.94 billion in 2026 at a CAGR of 12%. The aging population profile of most countries contributed to the growth of the musculoskeletal disorders drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.1 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to data protection such as the European Union's General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes. For instance, according to a study on 100 Data Privacy and Data Security statistics for 2020, GDPR compliance is a top priority for 58% of European companies. The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA). It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the musculoskeletal disorders drugs market. Going forward, the market for muscle relaxants is expected to increase with the rise in combination therapy. Combination therapy involves use of more than one medication or drug to treat a disease. These combinational therapies reduce the frequency of drug administration. For instance, in May 2019, Galt Pharmaceuticals has submitted a Supplemental Abbreviated New Drug Application to the U.S. Food and Drug Administration for Orphengesic Forte an oral formulation of aspirin, caffeine, and orphenadrine for the treatment of pain caused due to musculoskeletal disorders. Major companies in the musculoskeletal disorders drugs market include Sanofi S.A, Pfizer Inc., Bristol-Myers Squibb, Eli Lilly And Company, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc, Procter & Gamble, Eisai Co. Ltd, Biogen Inc and Sino Biopharmaceutical. North America was the largest region in the musculoskeletal disorders drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the musculoskeletal disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the musculoskeletal disorders drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global musculoskeletal disorders drugs market is segmented - 1) By Type: Drugs for Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs